Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing Jun. 25, 2025 5:00 PM ET Tempus AI, Inc. (TEM) ...

The Ambry CARE Program® leverages digital health solutions to enable health systems to stratify patients by cancer risks, driving personalized, proactive care.

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of ...

Ambry Genetics’ Patient for Life™ program helps provide diagnoses for rare diseases by reanalyzing exome sequencing data, offering hope to patients with undiagnosed conditions.

Ambry Genetics' Patient for Life program is supported by a dedicated team of scientists who continuously analyze emerging data on gene-disease associations and variant pathogenicity. This evidence is ...

ALISO VIEJO, Calif., May 27, 2025--New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

With increased demand for cancer genetic testing (GT), providers are exploring alternative service delivery models such as video education (VE). We compare the uptake of GT among 250 patients with ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Tempus AI, Inc.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc.